Combatting the second COVID 19 wave in India: Defining the role of Favipiravir
As India battles the second COVID-19 wave across all states, the healthcare system is overburdened with daily cases skyrocketing to more than 1.5 lac per day. There is a dire need for antiviral drugs that can reduce the severity and/or the duration of the illness in infected patients. Developing a new vaccine or a new antiviral drug takes a tremendous amount of resources and time. For instance, the first licensed COVID-19 vaccines were launched after almost a year from the documentation of index case in India. Developing a new antiviral drug may take even longer.